Rifampin is an oral antibacterial agent that belongs to the rifamycin class and is used primarily to treat bacterial infections. Therapeutically it is employed as a first-line component of combination regimens for tuberculosis and leprosy. The drug exerts its effect by binding to the bacterial dna-dependent rna polymerase, which blocks transcription initiation. This inhibition halts the synthesis of essential bacterial mrna and proteins, leading to rapid bactericidal activity. Rifampin is absorbed rapidly from the gastrointestinal tract, undergoes minimal hepatic metabolism, and is excreted primarily unchanged in the urine. The high plasma concentrations achieved after dosing maintain sustained suppression of bacterial transcription throughout the dosing interval. The combination of potent rna polymerase inhibition and favorable pharmacokinetics underlies its central role in multidrug therapy.

Rifampin is an antibiotic that belongs to the rifamycin class and is used primarily to treat bacterial infections. It is taken orally and works by binding to the beta subunit of bacterial rna polymerase to block transcription. This interaction prevents rna synthesis in the pathogen and leads to a halt in protein production. Because human rna polymerase is not significantly affected the drug selectively harms only the invading microbes. Clinically Rifampin is employed in the therapy of tuberculosis leprosy and certain gram positive infections. Its therapeutic role relies on high plasma concentrations that sterilize intracellular reservoirs of disease. Through selective inhibition of bacterial transcription the medication provides a bactericidal effect that underlies its inclusion in multidrug regimens.

The most common side effects reported include temporary fatigue, mild headache, and occasional nausea. Some people experience injection site soreness or redness without requiring medical attention. Light shivering or a low grade fever may occur shortly after vaccination. Muscle aches and joint stiffness are also frequently documented in clinical studies. These reactions are generally short lived and resolve within a few days. The occurrence rates vary by age group and vaccine type but remain consistent across trials.

The most common side effects often include mild symptoms such as headache and nausea. Fatigue is frequently reported especially during the first few days of treatment. Some people experience dizziness or light-headedness when standing up quickly. Dry mouth and mild stomach discomfort are also observed in many individuals. Occasional loss of appetite may occur alongside mild fever in a small number of cases. Muscle aches are noted occasionally usually resolving without intervention. A temporary skin rash can develop typically fading within a short period. These effects are generally mild and tend to diminish as the body adjusts to the regimen.